SCHEMBL23218407

SCHEMBL23218407

CCOC(=O)Cc1ccccc1OCc1ccc(C2CC2)c2oc(Cl)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.39
CFD P00746 2/20 0.39
TBXAS1 P24557 1/20 0.38
NPC1 O15118 1/20 0.37
PDCD1 Q15116 5/20 0.36
CD274 Q9NZQ7 5/20 0.36
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
PKM P14618 1/20 0.34
POLB P06746 1/20 0.34
DUSP3 P51452 1/20 0.34
PTPN5 P54829 1/20 0.34
CASP6 P55212 1/20 0.34
PTPN11 Q06124 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
NOD2 Q9HC29 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853103 1.00 PTGDR2 (0.39) PTGDR2CFDTBXAS1NPC1PDCD1
SCHEMBL23218393 0.85 TBXAS1 (0.40) PTGDR2CFDTBXAS1NPC1PKM
SCHEMBL23218608 0.82 CFD (0.51) PTGDR2CFDTBXAS1CYP2D6PLG
SCHEMBL29853038 0.82 CFD (0.51) PTGDR2CFDTBXAS1CYP2D6PLG
SCHEMBL23219179 0.82 TBXAS1 (0.43) PTGDR2CFDTBXAS1NPC1PKM
SCHEMBL29592646 0.82 TBXAS1 (0.43) PTGDR2CFDTBXAS1NPC1PKM
SCHEMBL23218713 0.81 PTGDR2 (0.39) PTGDR2CFDTBXAS1NPC1PSEN1
SCHEMBL29852542 0.81 PTGDR2 (0.39) PTGDR2CFDTBXAS1NPC1PSEN1
SCHEMBL29853033 0.73 CFD (0.51) CFDF2F9F10PLG
SCHEMBL21438612 0.72 CFD (0.42) CFDTBXAS1NPC1PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PTGDR2 484/4885CFD 1/4885TBXAS1 963/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTGDR2 976/4885CFD 1/4885TBXAS1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.